Equities

Hypera SA

Hypera SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (BRL)28.96
  • Today's Change-0.32 / -1.09%
  • Shares traded1.52m
  • 1 Year change-24.66%
  • Beta0.8339
Data delayed at least 15 minutes, as of Sep 18 2024 10:47 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.

  • Revenue in BRL (TTM)8.00bn
  • Net income in BRL1.69bn
  • Incorporated2001
  • Employees9.00k
  • Location
    Hypera SARua Nova Cidade, 404, Vila OlimpiaSAO PAULO 04.547-070BrazilBRA
  • Phone+55 1 136274206
  • Fax+55 1 136274371
  • Websitehttps://www.hypera.com.br/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hubei Jumpcan Pharmaceutical Co Ltd6.99bn2.18bn17.39bn5.23k7.971.67--2.493.073.079.8514.650.52623.094.601,732,306.0016.4116.2321.9220.8879.0682.6431.2024.423.13--0.11641.767.326.0230.0410.83-14.701.11
Pfizer Ltd1.45bn397.26m17.41bn1.72k43.83--39.8211.99133.01133.01486.27--------12,926,610.00--14.22--17.7165.0661.3727.3524.05--43.74--82.67-9.551.05-11.645.1433.359.24
Gan & Lee Pharmaceuticals2.08bn389.32m17.74bn4.48k43.702.10--8.540.87590.87594.6518.260.23750.88258.31600,884.604.458.304.788.8372.1585.3918.7526.447.05--0.000513.6552.311.78177.37-18.301.50--
Natco Pharma Ltd.2.76bn1.07bn18.04bn4.02k16.89--15.156.5591.3791.37235.68--------10,510,210.00--12.33--14.2583.4073.0538.7725.16--91.13--18.9647.7213.8194.0916.59-5.7614.87
Kangmei Pharmaceutical Co Ltd3.83bn188.28m18.18bn4.41k96.103.34--4.740.01770.01770.35960.50950.34471.392.501,127,547.001.71-17.602.59-32.2421.52-72.784.96-101.190.8735--0.1544--16.60-22.17103.81-22.83-53.51--
Zhejiang Huahai Pharmaceutical Co., Ltd.7.05bn779.09m18.30bn8.22k23.132.70--2.600.69950.69956.326.000.46811.093.231,112,139.005.165.677.358.0760.2760.5211.0311.610.85475.520.450633.550.519910.28-28.8850.517.21--
Hypera SA8.00bn1.69bn18.34bn9.00k10.911.529.412.292.652.6512.5419.000.32541.442.76--6.888.298.359.9861.8663.4921.1326.011.46--0.463750.184.8816.27-3.307.7429.8310.24
J B Chemicals and Pharmaceuticals Ltd2.35bn383.31m18.83bn5.31k50.21--39.258.0336.9936.99226.16--------6,764,044.00--15.77--18.8966.2761.1816.3416.06--21.04--33.0810.6316.2234.8423.3640.1537.42
Emcure Pharmaceuticals Ltd-6.53bn-6.53bn18.85bn11.15k--------------------------7.14--13.93--59.29--7.81------0.0011.237.14-6.3621.35-5.93--
Xiamen Amoytop Biotech Co Ltd1.84bn507.16m18.98bn1.96k37.4312.22--10.311.621.625.874.951.120.87515.891,217,627.0030.8117.9635.4721.0292.9790.4827.5519.173.34--0.00526.9537.5536.1993.52103.2881.61--
Suven Pharmaceuticals Ltd610.07m156.98m19.02bn1.05k121.06--98.4831.189.469.4636.75--------8,883,019.00--23.17--26.2056.5958.8525.7333.21--33.74--18.63-21.5622.71-26.9922.41-1.83--
Data as of Sep 18 2024. Currency figures normalised to Hypera SA's reporting currency: Brazilian Real BRL

Institutional shareholders

24.04%Per cent of shares held by top holders
HolderShares% Held
BV Distribuidora de T�tulos e Valores Mobili�rios Ltda.as of 09 Apr 202432.40m5.12%
Capital Research & Management Co. (World Investors)as of 05 Sep 202429.46m4.65%
Capital International Ltd.as of 30 Jun 202419.84m3.13%
Fidelity Management & Research Co. LLCas of 31 Jul 202419.20m3.03%
The Vanguard Group, Inc.as of 04 Sep 202415.26m2.41%
BlackRock Fund Advisorsas of 05 Sep 202410.39m1.64%
MFS International (UK) Ltd.as of 31 Jul 20247.79m1.23%
UBS Asset Management (Singapore) Ltd.as of 30 Jun 20247.19m1.14%
Vontobel Asset Management AGas of 30 Aug 20245.66m0.89%
BTG Pactual WM Gest�o de Recursos Ltda.as of 31 May 20245.10m0.81%
More ▼
Data from 31 May 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.